Showing 651-660 of 9295 results for "".
Part 2, 1726 nm lasers: All about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24340/Chapter 2 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods.Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvThe Future of Customized Treatments Within the Atopic Dermatitis Pipeline
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-future-of-customized-treatments-within-the-atopic-dermatitis-pipeline/37165/Practical Dermatology Editorial Board member Peter Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine, discusses the potential impact of new developments in atopic dermatitis research.Research Highlights Disparities in AD Care
https://practicaldermatology.com/programs/practical-dermatology/research-highlights-disparities-in-ad-care/36472/In this episode of DermwireTV, research on socioeconomic disparities in atopic dermatitis care; new information on guselkumab for scalp psoriasis in diverse skin tones; the impact of air quality on dermatitis; and a C-Suite Chat with Anastasia Georgievskaya, founder of Haut.AI.Noah Worcester 2024: Dr. Mesinkovska on Alopecia Areata
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-mesinkovska-alopecia-areata/24586/Natasha Atanaskova Mesinkovska. MD, PhD, summarizes her lecture on JAK inhibitors and minoxidil at the 2024 Noah Worcester Dermatological Society meeting.DermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinWhat’s on the Horizon for Acne?
https://practicaldermatology.com/conferences/maui-derm-2024/whats-on-the-horizon-for-acne/20254/Julie C. Harper, MD, explains her Maui Derm presentation, including an overview of the many potential treatments for acne that are on the horizon, such as a possible acne vaccine.How Combination Treatments Can Address Unmet Needs
https://practicaldermatology.com/conferences/maui-derm-2024/how-combination-treatments-can-address-unmet-needs/20243/Suneel Chilukuri, MD, talks with Chief Medical Editor Neal Bhatia, MD, about the progress cosmetic dermatology has made to fill previous gaps in options to address areas such as the chest, neck, and knees, especially with the range of advanced devices that often produce even better results when usedHow to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.DermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)